AstraZeneca Aims to Redefine Breast Cancer Care With New Data Across the Treatment Spectrum At SABCS 2022

WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca will present new data advancing its ambition to redefine care at the 2022 San Antonio Breast Cancer Symposium (SABCS), December 6-10, 2022. Twelve AstraZeneca medicines and potential new medicines will be featured in 55 presentations, including five oral presentations, showcasing the Company’s growing leadership across different subtypes and stages of breast cancer. Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: “Ou
Click here to view original post